Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTate & Lyle Regulatory News (TATE)

Share Price Information for Tate & Lyle (TATE)

Share Price is delayed by 15 minutes
Get Live Data
504.50    -0.50 (-0.10%)
Bid:
502.00
Ask:
503.00
Spread: 1.00 (0.199%)
Market Cap: £2.23b
TATE Live PriceLast checked at - London Stock Exchange

Intraday Tate & Lyle Share Chart

Director Declaration

10 Nov 2025 14:40

RNS Number : 9211G
Tate & Lyle PLC
10 November 2025
Β 

10 November 2025

Β 

Tate & Lyle PLC

Β 

Β 

DIRECTOR DECLARATION

Β 

Notification regarding external directorships

Β 

In accordance with Listing Rule 6.4.9(2), Tate & Lyle PLC announces that Sarah Kuijlaars, Chief Financial Officer, has notified the Company that she has been appointed as a non-executive director of JD Sports Fashion Plc (with effect from 10 November 2025).

Β 

On appointment, Sarah will become a member of the Audit and Risk Committee and the Nomination Committee. Sarah will be appointed as Chair of the Audit and Risk Committee with effect from 1 June 2026.

Β 

Β 

END

Β 

For more information contact:

Β 

For Tate & Lyle PLC

Β 

Investors and analysts

Christopher Marsh, VP Investor Relations

Tel: Mobile: +44 (0) 7796 192 688

Β 

Media

Nick Hasell, FTI Consulting

Tel: Mobile: +44 (0) 7825 523 383

Tel: Office: +44 (0) 203 727 1340

Email: tate@fticonsulting.com

Β 

About Tate & Lyle PLC:

Β 

Supported by our 165-year history of ingredient innovation, we partner with customers to provide consumers with healthier and tastier choices when they eat and drink. We are proud that millions of people around the world consume products containing our ingredients and solutions every day.

Β 

Through our leading expertise in sweetening, mouthfeel and fortification, we develop ingredients and solutions which reduce sugar, calories and fat, add fibre and protein, and provide texture and stability to food and drink in categories including beverages, dairy, bakery, snacks, soups, sauces, and dressings.

Β 

Tate & Lyle recently acquired CP Kelco, a leading provider of pectin, speciality gums and other nature-based ingredients to create a leader in mouthfeel, significantly enhancing our solutions capabilities. Following this combination, we now have more than 5,000 employees working in around 75 locations in 38 countries, serving customers in more than 120 countries. Science, Solutions, Society is our brand promise and how we will achieve our purpose of Transforming Lives through the Science of Food. By living our purpose, we believe we can successfully grow our business and have a positive impact on society. We live our purpose in three ways, by supporting healthy living, building thriving communities and caring for our planet.

Β 

Tate & Lyle is listed on the London Stock Exchange under the symbol TATE.L. American Depositary Receipts trade under TATYY. For the year ended 31 March 2025, and on a pro forma basis which assumes for illustrative purposes that the combination with CP Kelco took place on 1 April 2024, revenue for the enlarged Tate & Lyle Group would have been Β£2.12 billion. For more information, please visit www.tateandlyle.com or follow Tate & Lyle on LinkedIn,Β X (Twitter),Β FacebookΒ orΒ YouTube.

Β 

Β 

Β 

Β 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Β 
END
Β 
Β 
RDNZBLFFEFLXFBK
Date   Source Headline
12th Jul 202411:00 amRNSBlock listing Interim Review
11th Jul 20245:30 pmRNSTransaction in Own Shares
10th Jul 20245:41 pmRNSTransaction in Own Shares
9th Jul 20245:24 pmRNSTransaction in Own Shares
8th Jul 20245:41 pmRNSTransaction in Own Shares
5th Jul 20245:49 pmRNSTransaction in Own Shares
5th Jul 20242:00 pmRNSDirector/PDMR Shareholding
4th Jul 20245:40 pmRNSTransaction in Own Shares
3rd Jul 20245:29 pmRNSTransaction in Own Shares
2nd Jul 20245:32 pmRNSTransaction in Own Shares
2nd Jul 202411:30 amRNSHolding(s) in Company
1st Jul 20245:29 pmRNSTransaction in Own Shares
1st Jul 202412:30 pmRNSTotal Voting Rights
28th Jun 20245:59 pmRNSTransaction in Own Shares
27th Jun 20245:37 pmRNSTransaction in Own Shares
27th Jun 20244:30 pmRNSCompletes sale of remaining interest in Primient
27th Jun 20243:30 pmRNSHolding(s) in Company
26th Jun 20245:38 pmRNSTransaction in Own Shares
25th Jun 20245:50 pmRNSTransaction in Own Shares
24th Jun 20245:35 pmRNSTransaction in Own Shares
24th Jun 20243:30 pmRNSHolding(s) in Company
21st Jun 20245:45 pmRNSTransaction in Own Shares
21st Jun 20242:45 pmRNSUpdate to the Notice of AGM 2024
20th Jun 20246:03 pmRNSTransaction in Own Shares
20th Jun 20247:05 amRNSLaunch of Share Buyback
20th Jun 20247:00 amRNSCombination of Tate & Lyle and CP Kelco
4th Jun 20245:22 pmRNSAnnual Financial Report and Notice of AGM
4th Jun 202411:00 amRNSDirector/PDMR Shareholding
3rd Jun 202412:00 pmRNSTotal Voting Rights
30th May 202412:15 pmRNSHolding(s) in Company
23rd May 20247:00 amRNSFinal Results
23rd May 20247:00 amRNSSale of remaining interest in Primient JV to KPS
20th May 20241:00 pmRNSDirectorate Change
17th May 20243:30 pmRNSHolding(s) in Company
14th May 20243:30 pmRNSHolding(s) in Company
13th May 202410:00 amRNSHolding(s) in Company
8th May 20243:15 pmRNSHolding(s) in Company
1st May 20242:30 pmRNSTotal Voting Rights
25th Apr 20243:45 pmRNSHolding(s) in Company
24th Apr 20247:00 amRNSDirectorate Change
22nd Apr 20242:30 pmRNSDirector/PDMR Shareholding
19th Apr 202410:15 amRNSHolding(s) in Company
17th Apr 20244:15 pmRNSHolding(s) in Company
17th Apr 202410:30 amRNSHolding(s) in Company
15th Apr 202410:30 amRNSHolding(s) in Company
10th Apr 20243:45 pmRNSHolding(s) in Company
8th Apr 202411:15 amRNSHolding(s) in Company
5th Apr 20243:45 pmRNSHolding(s) in Company
4th Apr 20244:15 pmRNSHolding(s) in Company
4th Apr 202412:30 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.